Contact
Please use this form to send email to PR contact of this press release:
Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
TO:
Please use this form to send email to PR contact of this press release:
Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
TO: